Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: An option for improving treatment efficiency

Retina

Volumn 30, Issue 8, 2010, Pages 1190-1196

  Mataix, Jorge ^a   Palacios, Elena ^a   Carmen, Desco M ^a   Garcia Pous, Maria ^a   Navea, Amparo ^a  

^a Fundacion Oftalmologica del Mediterraneo   (Spain)

Author keywords

age related macular degeneration; choroidal neovascularization; combined therapy; photodynamic therapy; ranibizumab

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT PLANNING; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77957559347     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181d2f172     Document Type: Article

References (34)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1432-1444.
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
4. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2009 May 20 [Epub ahead of print].
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
6. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, WolfSchnurrbusch UE. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-837.
7. Mantel I, Zografos L, Ambresin A. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmologica 2008;222:321-323.
8. Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U. Ranibizumab for treatment of exudative age-related macular degeneration - own experience [in Polish]. Klin Oczna 2007;109:402-409.
9. Kloos P, Bernasconi P, Estermann S, Bachmann B, Rutishauser Y, Thölen A. Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration. Klin Monbl Augenheilkd 2008;225:385-391.
10. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009;223:370-375.
11. Costagliola C, Semeraro F, Cipollone U, Rinaldi M, della Corte M, Romano MR. Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009;247:1031-1037.
12. Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65.
13. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye diseases. Prog Retin Eye Res 2003;22:1-29.
14. Ferrara N, Gerber H-P, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003;9:660-676.
15. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;271:7788-7795.
16. Mataix J, Desco MC, Palacios E, Garcia-Pous M, Navea A. Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study. Ophthalmic Surg Lasers Imaging 2009;40:277-284.
17. Ruiz-Moreno JM, Montero J, Zarbin M. Photodynamic therapy and high dose intravitreal triamcinolone treat exudative age-related macular degeneration: 2 year outcome. Retina 2007;27: 458-461.
18. Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration. Retina 2009;29:13-19.
19. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008;28:675-681.
20. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-1185.
21. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-993.
22. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photo-dynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
23. Fingar VH, Vascular effect of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-328.
24. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photo dynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45: 195-214.
25. Heier JS, Boyer DS, Ciulla TA, et al; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006;124: 1532-1542.
26. Kiss CG, Simader C, Michels S, Schmidt-Erfurth U. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the PROTECT study. Br J Ophthalmol 2008;92:1620-1627.
27. Kumar A, Gopalakrishnan K, Sinha S. Combination photo-dynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study. Retina 2008; 28:1132-1137.
28. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.
29. Kaiser PK, Boyer DS, Garcia R, et al. Verteporfin photo-dynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747-775.
30. Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 2004;137:504-510.
31. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009;29:723-731.
32. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmaco-therapy in age-related macular degeneration? Ophthalmology 2008;115:2199-2205.
33. Falavarjani KG, Modarres M. Bevacizumab tachyphylaxis. Ophthalmology 2009;116:1016-1017.
34. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:3115-3120.